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Summary
The hepatitis C virus (HCV) is a growing global health
problem.Smallmolecules that interferewithhost-viral in-
teractions can serve as powerful tools for elucidating the
molecular mechanisms of pathogenesis and defining
new strategies for therapeutic development. Using a
cell-based screen involving subgenomic HCV replicons,
we identified the ability of 18 different abscisic acid
(ABA) analogs, originally developed as plant growth reg-
ulators, to inhibit HCV replication. Three of these were
further studied. One compound, here named origamicin,
showed antiviral activity through the inhibition of host
proteins involved in protein folding. Origamicin could
thereforebeanimportant tool forstudyingthematuration
ofbothhostandviral proteins.Hereinwedemonstratean
application for molecular scaffolds based on ABA for
mammalian cell targets involved in protein folding.
Introduction
Affecting over 170 million individuals worldwide, the
hepatitis C virus (HCV) is a growing threat to global
health [1]. No vaccine currently exists, and the availabil-
ity of clinical treatments is limited [2–8]. HCV is a posi-
tive-strand RNA virus of the Flaviviridae family and has
an w9.6 kb genome (Figure 1), which encodes for an
w3000 amino acid polyprotein that is posttranslationally
cleaved into functional components [9, 10]. The HCV ge-
nome encodes for both structural proteins, which make
up the virion particles (the core protein and envelope
proteins, E1 and E2), and nonstructural proteins (NS2–
NS5B). The NS3 protein is a protease that, in conjunction
with NS4A, mediates all cleavages in the NS3–NS5B re-
gion [9, 10]. NS3 also has nucleoside triphosphatase and
helicase activities. NS5A is a highly phosphorylated pro-
*Correspondence: john.pezacki@nrc-cnrc.gc.catein that is thought to be involved in the resistance to in-
terferon a [9, 10]. NS5B is an RNA-dependent RNA poly-
merase. Given the global health issue presented by HCV,
there is great interest in elucidating the role of host-virus
protein interactions in propagation. The functional col-
laboration between host and virus proteins that is re-
quired for HCV to replicate defines the molecular basis
of pathogenesis, and it represents a suitable target for
drug development [11]. In fact, HCV relies on host as
well as viral proteins for posttranslational modifications
of the initially translated HCV polyprotein. These modifi-
cations are essential for maturation of the structural and
nonstructural proteins. For example, a host cell ER signal
peptidase cleaves the HCV polyprotein to yield immature
structural proteins that are then glycosylated by other
host cell proteins [10]. The glycosylation of the HCV E1
and E2 envelope proteins by host glycosidases is of
particular importance to HCV virulence because it is re-
quired for viral particle formation and budding, efficient
host cell recognition, and viral entry [12, 13].
High-throughput techniques including gene expres-
sion profiling [14, 15] and proteomics approaches have
identified a number of important host-virus interactions
in cell culture models for HCV replication and in HCV
infection [16–20]. Small-molecule-based antiviral strate-
gies have also demonstrated success in inhibiting HCV
in clinical infections [21]. There is much promise in the
use of chemical genetic approaches [22, 23] to discover
new host-pathogen interactions because many dynamic
molecular interactions are not easily identified. Chemi-
cal genetics approaches have uncovered cell-perme-
able small molecules that disrupt protein function in cel-
lular processes such as mitosis [24], cell signaling [25],
and tissue regeneration [26]. Here, we have combined
small-molecule screening with activity-based inhibitor
profiling [27] to identify natural product-like inhibitors
of HCV replication and to determine the target proteins
to which these inhibitors bind. Our small-molecule li-
brary is based on the plant hormone (+)-S-abscisic
acid (ABA), which is a carotenoid-derived sesquiter-
pene. ABA is involved in the regulation of numerous
physiological processes in plant growth and develop-
ment, including embryo and seed development, protein
storage, and stress responses [28]. Many analogs of
ABA have been synthesized for structure-activity stud-
ies and to develop growth regulators with enhanced
and prolonged activity [29–33]. ABA also has a high de-
gree of structural similarity to terpenoid ligands such as
retinoic acid, as well as synthetic mammalian nuclear
hormone receptor ligands [34, 35]. Since we recently
found that antagonists of peroxisome proliferator-acti-
vated receptor (PPAR) block HCV replication [36], we
sought to determine if any ABA analogs previously de-
veloped to identify biologically active plant growth reg-
ulators would show any anti-HCV activity.
Results and Discussion
In order to determine whether analogs with the ABA scaf-
fold demonstrate activity against HCV, a 100 compound
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1052Figure 1. Activity of ABA Analogs in HCV Replicon-Bearing Huh-7 Human Hepatoma Cells
(A) Schematic representations of the HCV genome and the HCV replicons used in this study.
(B) Chemical structures.
(C) Luciferase reporter gene activity of HCV replicons expressing the luciferase gene. Activities were determined at 100 mM concentration after
24 hr treatments.
(D) Percent maximum signal versus concentration plots from which IC50
Replicon values were determined for origamicin, A2-PBI-659, and
C1-PBI-575 after a 24 hr treatment.
(E) Luciferase reporter gene activity of HCV replicons expressing the luciferase gene determined after a 24 hr treatment for the following com-
pounds: (6) origamicin at 30 mM, A2-PBI-659 at 20 mM, C1-PBI-575 at 5 mM; (+)-S-abscisic acid (ABA) and (2)-R-abscisic acid (ABA) at 100 mM;
retinoic acid (RA) at 100 mM; lovastatin at 50 mM; 25-hydroxycholesterol at 2.5 mM; (+) origamicin at 30 mM; (2) origamicin at 30 mM. ‘‘U’’ denotes
untreated cells.
Error bars represent the mean 6 SD.library of ABA analogs was screened with a tricistronic
subgenomic HCV replicon containing the genetic re-
porter firefly luciferase (Figure 1A) [36, 37]. All of the
ABA analogs contained the six-membered ring and
the unsaturated side chain with a variety of substituents(Figure 1B). For the initial screening, a concentration of
100 mM of the compounds was used. After a 24 hr treat-
ment, the Huh-7 cells harboring the tricistronic HCV re-
plicon were lysed, and the amount of HCV replication
was measured by using luciferase assays [36, 37]. Initial
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1053screening identified 18 ABA analogs that showed signif-
icant inhibitory activity in the genetic reporter assay for
HCV replication (Figure 1C). These analogs were then
tested for cytotoxicity at the same concentration, 100
mM,byquantifying lactatedehydrogenase (LDH),astable
cytosolic enzyme that is released upon cell lysis. Re-
leased LDH in culture supernatants is measured with
a 30 min coupled enzymatic assay, which results in the
conversion of a tetrazolium salt (INT) into a red formazan
product. The amount of color formed is proportional to
the number of lysed cells and is a direct measurement
of cell viability (see the Supplemental Data available
with this article online). Experiments showed that all of
the 18 compounds identified as having anti-HCV activity
in the luciferase assay displayed some degree of cyto-
toxicity at a 100 mM concentration, with cell viabilities
ranging from 9.4% to 70% compared to untreated cells
(see Figure S1 in the Supplemental Data). To determine
whether any of the compounds showed activity at lower
concentrations, we repeated the assay between 100 mM
and 50 nM concentrations (data not shown), and the
firefly luciferase and cytotoxicity assays of these com-
pounds showed that origamicin, A2-PBI-659, and C1-
PBI-575 had the greatest antiviral activity and only C1-
PBI-575 showed adverse cytotoxicity at concentrations
less than 100 mM (Figure S2).
We evaluated the efficacy of the three ABA analogs
toward HCV inhibition by using the tricistronic HCV
replicon (Figure 1A) and by measuring firefly luciferase
activity over a wide range of concentrations in order
to determine the IC50
Replicon values (Figure 1D). These
values were determined to be 20.5 6 2.5 mM, 10.6 6
6.5 mM, and 1.98 6 0.42 mM for origamicin, A2-PBI-
659, and C1-PBI-575, respectively. At concentrations
at which cell viability was comparable, these analogs
showed similar or superior inhibitory effects compared
to the known HCV inhibitors 25-hydroxycholesterol
[15, 37, 38] (2.5 mM) and lovastatin [38] (50 mM) (Fig-
ure 1E). Treatment of the HCV replicon with 100 mM of
(+)-S-abscisic acid and (2)-R-abscisic acid did not af-
fect HCV replication (Figure 1E). The three above-men-
tioned ABA analogs showed similar cytotoxicity to that
of retinoic acid, a mammalian ortholog of ABA, at com-
parable concentrations (Figure S4). However, retinoic
acid showed much less activity against the HCV replicon
compared to the other small molecules (Figure 1E). Ex-
periments with the R and S isomers of origamicin and
HCV replicons were conducted at several concentra-
tions of ABA analog, and the results indicated that the
antiviral properties toward the HCV replicon are not
dependent on stereochemistry. The position of the hal-
ogen in origamicin was critical for its biological activity
(data not shown). For example, replacing the allylic
halide in origamicin or C1-PBI-575 with a propyl halide
eliminated the biological activity. The cytotoxicity of ha-
logenated electrophiles toward human liver cells has
been established previously [39].
In order to validate the luciferase assay data, the
effects of ABA analogs origamicin, A2-PBI-659, and
C1-PBI-575 on expression levels of HCV proteins were
measured by using a different bicistronic HCV replicon
(Figure 1A). Huh-7 cells stably supporting HCV replicon
propagation were treated with ABA analogs for 12–30
hr, after which the cells were lysed, the cellular proteinswere collected, and quantified western blots were per-
formed and probed against HCV NS3 and NS5A proteins
by using mouse anti-NS3 and anti-NS5A primary anti-
bodies (Figure 2A). Antibodies against the PTP1D pro-
tein showed that the concentrations used were not toxic
for the cells and that there was equal loading of proteins
on the blots. The western blots showed that compounds
origamicin, A2-PBI-659, and C1-PBI-575 inhibited HCV
NS5A protein production by w80%, 75%, and greater
than 90%, respectively, which was comparable to the in-
hibition exhibited by antiviral cytokine interferon g (IFNg)
(Figure 2A). Interestingly, after longer treatment with
ABA analogs origamicin and A2-PBI-659, the replicon
cells recovered and HCV replication resumed. In con-
trast, cells could be cured of HCV replicons by using
the ABA analog C1-PBI-575.
In order to determine if the inhibition of HCV replica-
tion was linked with changes in cellular viability based
on the cell number or morphology, we performed fluo-
rescence microscopy experiments on the tricistronic
HCV replicon treated with origamicin, A2-PBI-659, and
C1-PBI-575 at a variety of concentrations (Figure 2B).
Cells were treated for 48 hr, after which the nuclei
were stained with a mouse anti-NS5B primary antibody
and a fluorescein-labeled anti-mouse secondary anti-
body, followed by counterstaining with DAPI to label
the nuclei and Oil-Red O to visualize the lipid droplets.
We observed decreases in NS5B protein with origamicin
at 20 mM, with A2-PBI-659 at 20 mM, and with C1-PBI-
575 at 7 mM. However, cell viability, lipid droplet content,
and cell morphology were identical to those of the un-
treated cells. Fluorescence microscopy showed that at
these concentrations there was no change in cellular
viability, as shown by nuclear morphology, based on
DAPI; however, some cytotoxicity was observed ac-
cording to the LDH assay (Figure S3).
To investigate if HCV inhibition by the active ABA an-
alogs was due to interactions with the host Huh-7 hu-
man hepatoma proteins, or whether their activity and cy-
totoxicity were due to a specific interaction with HCV,
their cytotoxic effects were screened against a panel
of human cell lines. These cell lines included Huh-7,
HepG2 and C3A human hepatocarcinoma, MDA-MB-
435 human melanoma, HEK293 human epithelial kidney,
and HeLa cervical carcinoma cells (Figure S3). The re-
sults suggested that the host cell effects of origamicin,
A2-PBI-659, and C1-PBI-575 are cell-type specific. Hep-
atoma and kidney cells appeared to be most sensitive to
the effects of the ABA analogs, whereas HeLa cells
showed virtually no cytotoxicity upon treatment with
the ABA analogs, excepting high doses of C1-PBI-575
(R100 mM). Therefore, we conclude that the cytotoxic
effect at higher concentrations of ABA analogs is depen-
dent on cell type but does not require the expression of
HCV proteins.
As ABA and its analogs have similar molecular struc-
tures to retinoic acid and other nuclear hormone recep-
tor ligands, they may show reactivity toward these mam-
malian receptors. In order to test whether the ABA
analogs affect the RXR pathway, we performed the albu-
min ELISA assay with analogs origamicin, A2-PBI-659,
C1-PBI-575, as well as lovastatin, 25-hydroxycholes-
terol, and ABA, and we compared the results to those
with retinoic acid and untreated cells (Figure 2C). We
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1054Figure 2. Functional Validation of ABA Analog Activity in HCV Replicon-Bearing Huh-7 Human Hepatoma Cell Lines
(A) Western blots of HCV NS5A and NS3 proteins from subgenomic HCV replicons under various conditions. Lanes for C1-PBI-574 (upper left)
are: HCV replicon cells, untreated; mock treatment with 1% v/v MeOH; C1-PBI-575, 15 mM for a 12 hr treatment. Lanes for origamicin (upper
right) are: Huh-7 cells, untreated; origamicin, 50 mM for 30 hr, 25 hr, and 20 hr treatments, respectively; IFNg, 5 U/ml at 74 hr, 45 hr, and 20 hr
treatments, respectively; HCV replicons, untreated; and mock treatment with 1% v/v MeOH. Lanes for A2-PBI-569 (lower middle) are: IFNg,
5U/ml at 74 hr and 20 hr treatments, respectively; HCV replicons, untreated; mock treatment with 1% v/v MeOH; A2-PBI-569, 50 mM at
20 hr, 16 hr, and 13 hr treatments, respectively; Huh-7 cells, negative control. Blots were also probed for PTP1D expression to indicate the
loading consistency.
(B) Fluorescence microscopy of immunostained HCV replicon cells. Panels from top to bottom are: cell nuclei stained blue with 40,6-diamino-2-
phenylindole (DAPI), lipid droplets stained red with Oil Red O, HCV NS5B protein stained green, and the three-color overlay. ‘‘Mock’’ is treat-
ment with 1% v/v MeOH, the C1-PBI-575 analog is treated at 7 mM for 48 hr, the origamicin analog is treated at 20 mM for 48 hr, and the A2-PBI-
569 analog is treated at 20 mM for 48 hr.
(C) Secreted albumin (ng/ml) from HCV replicon-bearing cells as determined after a 24 hr treatment with the indicated compounds. Analog
concentrations are given in parentheses. Error bars represent the mean 6 SD, and asterisks indicate a significant difference (p < 0.05) relative
to the untreated HCV replicons.chose to investigate albumin levels because their secre-
tion is known to be directly modulated by retinoic acid.
Also, changes in albumin levels can be associated with
other effects on cell proliferation and differentiation by
ABA and its analogs [35, 40, 41]. Huh-7 cells stably ex-
pressing HCV replicons were treated with the analogs
for 24 hr, after which albumin ELISA assays were per-
formed. No significant reduction inalbumin was observed
upon treatment with ABA or the three analogs that
showed anti-HCV activity, in contrast to retinoic acid,
which did lower the secreted albumin levels as expected.
To understand the possible mechanisms by which the
ABA analogs give rise to antiviral activity against HCV,we utilized a chemical proteomics strategy to determine
the protein targets within the entire proteome [27]. We
applied inhibitor-based protein-profiling approaches to
investigate interactions of the ABA analog origamicin
on both host and viral proteomes isolated from the repli-
con systems. We exploited the alkyne functionality pres-
ent in origamicin to conjugate both rhodamine for in-gel
fluorescence experiments [27] and biotin for affinity
chromatography experiments by using ‘‘click’’ chemis-
try [42] (Figure 3A).
Our first experiments to identify the ABA targets in-
volved in vitro labeling of cytosolic and membrane pro-
teins from Huh-7 cells harboring HCV replicons by
Origamicin Inhibits HCV by Blocking PDI Function
1055Figure 3. Proteomics Analyses of Origamicin
Activity in HCV Replicon Cells and Huh-7
Parental Cells
(A) Scheme for azide-alkyne ‘‘click’’ coupling
reactions between origamicin and various
alkyl azides.
(B) In-gel fluorescence images of SDS-PAGE
gels containing labeled proteomes from ori-
gamicin-treated cells, where origamicin was
preincubated with cells for 24 hr at 30 mM
concentration, followed by proteome extrac-
tion and a ‘‘click’’ reaction of the isolated
proteome with RhN3. Arrows indicate four
strongly labeled proteins.
(C) Fluorescent and silver-stained two-dimen-
sional gel images of untreated control (Mock)
and treated (origamicin) Huh-7 cytosolic pro-
teins. Treated cells were preincubated for 24
hr with 30 mM origamicin, followed by protein
extraction and a ‘‘click’’ reaction of the iso-
lated proteins with RhN3. The mock gel was
done with proteins extracted from untreated
cells that were submitted to the same ‘‘click’’
reaction conditions. Arrows are pointing to
major spots that were chosen for protein iden-
tification by LC-MS/MS. Red arrows are point-
ing to spots containing protein of the PDI
family (PDIA1, PDIA3, PDIA4, and PDIA6).origamicin-Rh, followed by isolation of proteins with or-
igamicin-Bio. Four strong bands were observed upon in-
cubation of the biotin-labeled probe origamicin-Bio (Fig-
ure 3A) with cytosolic proteins that were purified and
identified via mass spectrometry (data not shown). Inter-
estingly, the four proteins were all host proteins impor-
tant for protein folding and trafficking, specifically heat
shock proteins and protein disulfide isomerase. We pos-
tulated that origamicin reacted with these targets as an
electrophile. The electophilic sites can be blocked with
cysteine, which can potentially reduce the activity of or-
igamicin. Luciferase assays involving the HCV replicon
indicated that preincubation of origamicin at 30 mM
with cysteine significantly reduced origamicin activity,
whereas preincubation of origamicin at 50 mM with cys-
teine only partially affected the activity of origamicin,
which can be attributed to reversible interconversion
between origamicin and its cysteine adduct. Statisticalanalysis showed that incubation with cysteine signifi-
cantly reduced the activity and toxicity of origamicin
(p < 0.05); however, some activity was retained and
cell viability did not completely recover in the presence
of cysteine, indicating that cysteine alone was insuffi-
cient to irreversibly block origamicin’s inhibitory activity
(Figure S5). Several examples exist whereby small-mol-
ecule inhibitors are modified prior to their interaction
with their target protein. For example, lactacystin is
known to undergo reversible interconversion between
a lactone and thioacyl intermediates [43–45].
In order to more specifically characterize the protein
targets of the ABA analog origamicin, in situ inhibitor-
based protein profiling was conducted. HCV replicon-
bearing cells were treated for 24 hr with the analog ori-
gamicin and origamicin preincubated with cysteine.
The cytosolic proteins were then extracted, and cop-
per-catalyzed click reactions were conducted to
Chemistry & Biology
1056Figure 4. Validation of Origamicin Activity toward Protein Disulfide Isomerase Proteins
(A) An in-gel fluorescence image of an SDS-PAGE gel containing pure yeast PDI incubated with various concentrations of origamicin-Rh (upper
panel) and Coomassie blue staining of the gel (lower panel).
(B) Fluorescence microscopy images of HCV replicon-bearing cells that were treated with origamicin-Rh (red, upper right) and counterstained
with antibodies against PDI (green, upper left). Nuclei (blue) are stained with 40,6-diamino-2-phenylindole (DAPI). The overlay in the lower panel
shows that nearly all origamicin-Rh is localized in the ER and colocalized with PDI.conjugate rhodamine to the proteins bound to the ABA
analogs. In-gel fluorescence again showed that origami-
cin interacted strongly with four proteins (Figure 3B). In
order to confirm the specificity and to determine other
possible protein targets for origamicin, we performed
two-dimensional gel electrophoresis experiments (Fig-
ure 3C). We observed 8 strongly fluorescent proteins
and 16 weakly labeled proteins. Proteins that were iden-
tified by nanoLC-MS/MS either had a cysteine-contain-
ing active site (e.g., protein disulfide isomerase family,
and, to a lesser extent, peroxiredoxin 1) or were known
phosphoproteins (e.g., heat-shock protein b-1, cofilin-
1, and nucleophosmin). The strongest fluorescence,
and thus the highest selectivity in labeling, was ob-
served with spots containing proteins of the PDI family
(PDIA1, PDIA3, PDIA4, and PDIA6), which all have two
cysteine-containing active sites. The targeting of PDI
proteins by origamicin is consistent with the reactivity
of other simpler halogenated organic molecules [39,
46, 47] that demonstrate a lower degree of target spec-
ificity and a much higher degree of cytotoxicity [39, 46,
47]. The full list of protein identities, protocols, and
methods is provided in Supplemental Data. One of the
cysteine-containing active site proteins that was identi-
fied is retinal dehydrogenase 1. This is consistent with
our original hypothesis that ABA analogs may show
crossreactivity to retinoic acid-binding proteins.
Since origamicin was found to interact strongly with
protein disulfide isomerases, we examined its interac-
tion with yeast PDI in vitro. We found that the interaction
of origamicin-Rh was concentration dependent and had
a micromolar binding constant (Figure 4A). We also ex-
amined whether origamicin showed subcellular localiza-
tion to the endoplasmic reticulum (ER), where protein
synthesis and folding occurs. We performed fluores-
cence microscopy on HCV replicon cells treated with or-
igamicin-Rh and counterstained with antibodies against
PDI. Origamicin-Rh did localize to the ER and colocal-
ized with PDI (Figure 4B).To demonstrate whether origamicin inhibits PDI activ-
ity, we conducted activity assays in Escherichia coli
strains JCB 570 and JCB 571, which differ only by the
disruption of the dsbA (disulfide bond A) gene. Knock-
out strains have a severely impaired capacity for disul-
fide bond formation, resulting in a range of defects, in-
cluding significantly reduced activity of the enzyme
alkaline phosphatase (AP) [48]. The mutant phenotype
can be reversed by heterologous expression of protein
disulfide isomerases [49]. This complementation can
be attributed directly to the restoration of enzymatically
catalyzed disulfide bond formation. The E. coli strain
JCB 571 has a transposon insertion in the dsbA gene,
thus eliminating endogenous disulfide oxidase activity.
An expression vector containing the Brassica carinata
PDI1 gene that contains a highly homologous active
site to that of human PDIs was previously introduced
into this mutant and was used to demonstrate PDI activ-
ity in the encoded protein (unpublished data). We con-
ducted PDI inhibition assays by using cultures of the
JCB 571 transformant and a wild-type strain (JCB 570).
These were incubated with origamicin as well as ABA
as a control prior to evaluating PDI activity via a colori-
metric assay of AP activity [50, 51]. The AP activity in
the wild-type strain was unaffected by concentrations
of origamicin ranging from 0 to 1 mM (Figure 5). How-
ever, a dose-dependent decrease in AP activity was
observed in the dsbA mutant expressing a Brassica
carinata PDI (Figure 5). These observations show that
origamicin targets eukaryotic PDIs and is able to distin-
guish between B. carinata PDI and the bacterial DsbA.
The E. coliDsbA is a 21 kDa soluble protein composed
of a single thioredoxin fold and a CXXC active site motif.
It is a strong catalyst of protein/peptide cysteine oxida-
tion and has some isomerase activity. However, it is
DsbC, as a dimeric enzyme, that is primarily responsible
for the isomerization of incorrect disulfide bonds. DsbC
is a 25 kDa protein and, similarly to DsbA, has a single
thioredoxin fold and active site motif. In contrast, human
Origamicin Inhibits HCV by Blocking PDI Function
1057and plant PDI arew55 kDa proteins, each with two thi-
oredoxin folds and two active site motifs. These en-
zymes catalyze both cysteine oxidation and disulfide
bond isomerization [52, 53]. Furthermore, a study of
complementation of dsbA and dsbC mutants with muta-
genized human PDI indicated that residues in both
active site motifs of the human PDI were involved in re-
storing AP activity [54]. Therefore, it is likely that the
structural differences are responsible for the difference
in response to origamicin between prokaryotic and eu-
karyotic enzymes.
It is known that a number of HCV proteins also coloc-
alize with PDI in the ER. Therefore, small-molecule per-
turbation of PDI and the resultant induction of ER stress
[55–61] could affect the proper maturation of HCV pro-
Figure 5. Evaluation of Origamicin Dosage Effects in a Protein
Disulfide Isomerase Inhibition Assay
Cultures of Escherichia coli (570 = wild-type; 571 A7 = dsbA mutant
expressing a Brassica carinata PDI) were incubated with 0, 0.1,
0.5, or 1.0 mM origamicin for 4 hr at 37C. The activity of PDI was
subsequently assessed by measuring alkaline phosphatase (AP)
activity. Error bars represent the standard deviation between
measurements.teins and disrupt the environment of HCV replication
complexes. Also, the disruption of the HIV lifecycle by
blocking PDI function has been demonstrated by using
the antimicrobial peptide bacitracin and anti-PDI anti-
bodies [55, 56, 60, 61]. Protein disulfide isomerase func-
tion is required for the reduction of two disulfide bonds
of HIV envelope glycoprotein 120 [55, 60, 61]. Inhibitors
of PDI block cleavage of disulfide bonds in receptor-
bound glycoprotein 120 and prevent HIV-1 entry [55].
Small molecules that target the ER have great potential
as tools for cell biology because of the numerous funda-
mental processes that occur on the ER membrane. This
is particularly true for HCV, for many other RNA viruses
that replicate on the ER, and for those that require the
protein-folding machinery for proper virion particle as-
sembly [55–61]. The subcellular localization of origami-
cin is most likely linked to the high degree of specificity
that it displays toward isoforms of PDI that reside in the
ER. This feature helps establish it as a tool for under-
standing PDI function.
Origamicin’s main protein targets in Huh-7 cells are
protein disulfide isomerases. Dysfunction of these pro-
teins can lead to ER stress due to the misfolding of
both host and virus proteins, which, in turn, leads to un-
folded protein response. It is known that HCV gene
expression occurs on the ER and in itself induces ER
stress. HCV also blocks the normal unfolded protein re-
sponse and the resultant increase in protein degradation
by suppressing the IRE1-XBP1 pathway, demonstrated
in HCV replicons [62]. Cellular protein-folding machinery
is necessary for the maturation of the HCV proteome.
There are a number of disulfide bonds that are critical
to HCV proteins, including the envelope proteins E1
and E2 as well as the NS5A protein [63–65]. PDI has
also been shown to be important in maintaining the
HIV envelope protein (Env) through reduction of the
gp120 glycoprotein component [55–61]. The HCV NS3
serine protease and NS4A cofactor both colocalize
with PDI, suggesting that their assembly and function
are linked to these ER proteins. Therefore, we have pro-
posed a model for the mechanism by which origamicin
inhibits HCV replication (Figure 6). Although it is possible
that other mechanisms are responsible for the antiviralFigure 6. A Proposed Scheme for How Ori-
gamicin Inhibits HCV Replication
Chemistry & Biology
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con RNA can be translated by ribosomes into polypro-
teins and can be posttranslationally processed into im-
mature proteins, but that origamicin prevents the
proper folding of the precursor proteins, thus preventing
the formation of mature viral proteins.
Significance
We have used chemical genetics approaches to estab-
lish a cell-permeable small-moleculemodulator of pro-
tein folding that also acts as an inhibitor of HCV repli-
cation by blocking a critical host cell pathway that we
believe is essential to the viral lifecycle. The protein
targets of origamicin were determined by using inhib-
itor-based protein-profiling techniques that utilized in
vivo reactions of origamicin with the HCV replicon
cells, followed by a ‘‘click’’ reaction of the extracted
proteins with either rhodamine or biotin labels. The
major target for origamicin was found to be protein
disulfide isomerase, a major component of the ER.
To our knowledge, we herein establish a new way of
targeting these specific ER proteins. We demonstrate
that transient blocking of this host protein can block
HCV replication in HCV replicons without permanently
influencing cell viability, and we establish a strategy
for anti-HCV compound development. Since orgami-
cin is a close structural analog of a naturally occurring
plant metabolite, originally developed as a plant
growth regulator, its potency and specificity toward
human proteins is surprising. These results demon-
strate the opportunities for utilizing molecular scaf-
folds formultiple unrelated targets. There aremany ex-
amples of plant metabolites with significant biological
activity, and origamicin is another important example.
Experimental Procedures
Cell Culture and HCV Replicon Treatments
Cell monolayers of the human hepatoma cell line Huh-7 were grown
in Dulbecco’s modified Eagle’s medium (DMEM) (Invitrogen, Bur-
lington, ON) supplemented with 100 nM nonessential amino acids,
50 U/ml penicillin, 50 mg/ml streptomycin, and 10% fetal bovine se-
rum (FBS) (Cansera, Rexdale, ON). G418 was added to a concentra-
tion of 250 mg/ml to the Huh-7 cells stably expressing HCV replicons.
The pFK-I389neo/NS3-30/5.1 and pFK-I389neo/luc/NS3-30/5.1 plas-
mids that contain HCV subgenomic replicons were utilized as previ-
ously described [36, 37]. For detailed protocols, see Supplemental
Data.
LDH-Cytotoxicity Assay
Huh-7 cells harboring a subgenomic replicon were treated with small
molecules as described above. Cells were washed and lysed with Tri-
ton X-100, and the cytotoxicity was determined by using the CytoTox
96 Non-Radioactive Cytotoxicity Assay (Promega, Maddison, WI)
according to the manufacturer’s protocol. The absorbance was
read at 490/650 nm by using a Spectramax M2 plate reader (Molec-
ular Devices Corporation, Sunnyvale, CA).
Fluorescence Microscopy
Fluorescent imaging of Huh-7 cells stably expressing HCV replicons
was done by using an Axiovert 200M inverted microscope from Zeiss
(North York, ON) with the Axiovision 3.1 software and an AxioCam
connected to the microscope. For imaging of HCV proteins, cells
were washed and fixed with 3.7% formaldehyde for 30 min at room
temperature. Cells were probed with mouse anti-NS5B (5B-12B7)
primary antibody (1:100 dilution; kindly provided by Darius Morad-
pour, Department of Medicine, University of Freiburg, Germany),followed by incubation with Cy2-conjugated donkey anti-mouse
IgG secondary antibody (1:100 dilution; Jackson ImmunoResearch
Laboratories Inc., Westgrove, PA). Nuclei were stained with DAPI
(300 nM in PBS; Molecular Probes, Eugene, OR), and lipids were
stained with Oil Red O (0.5% in isopropanol; Sigma-Aldrich, Oakville,
ON). For imaging of the endoplasmic reticulum, cells at 70%–80%
confluency were treated with 30 mM origamicin-Rh for 30 min. Cells
were fixed and stained by using the Select FX Alexa Fluor 488 Endo-
plasmic Reticulum Labeling Kit (Molecular Probes) according to the
manufacturer’s protocol. Briefly, cells were washed with warm 13
PBS and fixed with 13 fixative solution at 37C for 15 min. Cells
were then permeabilized for 5 min. For ER staining, cells were stained
with anti-PDI primary antibody (1:1000) dilution for 2 hr at 25C, fol-
lowed by incubation with the Alexa Fluor 488 secondary antibody
at 25C for 30 min.
Western Blotting
Huh-7 cells harboring subgenomic replicons (1 3 106 cells) were
seeded in 60 mm dishes for preparation of western blot lysates. At
80% confluency, the cells were treated with small molecules. Cells
were washed and lysed with an SDS lysis buffer consisting of 50
mM Tris-HCl (pH 6.8), 2% SDS, and 10% glycerol. SDS-PAGE gels
and immunoblotting were then conducted as described previously
[36, 37].
Albumin ELISA
Albumin ELISA assay was performed by using the Human Albumin
ELISA Quantitation Kit (Bethyl Laboratories, Inc., Montgomery, TX)
and by following the manufacturer’s protocol. Readings were taken
at 450 nm by using a Spectramax M2 plate reader. See Supplemen-
tal Data.
Inhibitor-Based Protein Profiling
The proteins of HCV replicon-bearing Huh-7 cells as well as the pa-
rental cell line were probed under a variety of conditions by using ap-
proaches typically applied to activity-based protein profiling [27].
The description of the biotin and rhodamine linkers, ABA analog
conjugates, and detailed protocols for the proteomics studies per-
formed herein are available in Supplemental Data.
Analysis of PDI Activity in the Presence of Origamicin
Assessments of PDI inhibition by ABA analogs were performed in
Escherichia coli strains JCB 570 (araD139 D[ara-leu]7697 galU
galK DlacX74 rpsL thi phoR zih12::Tn10) and JCB 571 [48, 49], which
differ only by the disruption of the dsbA gene (dsbA::kan1). Both
strains were provided by J. Beckwith (Harvard Medical School, De-
partment of Microbiology and Molecular Genetics, Boston, MA). For
PDI inhibition assays, cultures of the JCB 571 transformant and
a wild-type strain (JCB 570) were incubated with analogs of ABA
prior to evaluating PDI activity via a colorimetric assay of AP activity
[50]. Specifically, bacterial strains were cultured overnight, with
shaking, at 37C in ‘‘121 peptone’’ medium [51]. For strain JCB
570, this medium was supplemented with 12 mg/ml tetracycline,
while media for cultures of JCB 571 transformants included both
25 mg/ml kanamycin and 50 mg/ml ampicillin. A total of 30 ml of
each overnight culture was added to 3 ml of the same media (as
two replicate subcultures). In addition, ABA and origamicin were
added to separate subcultures to a final concentration of either 0.1
or 0.5 mM. (The compounds were dissolved in DMSO for 100 mM
stock solutions; thus, control cultures contained either 0.1% or
0.5% DMSO.) Incubation continued for another 4 hr, after which 1
ml of each subculture was withdrawn and centrifuged at 6000 3 g,
and the supernatant was removed by aspiration. The bacterial pellet
was resuspended in 1 ml of 1 M Tris-HCl (pH 8.0) and was transferred
to a disposable cuvette (VWR). Two samples were prepared from
each subculture (i.e., two replicates). The optical density of each
sample when exposed to light at wavelengths of 420 and 600 nm
was recorded in a Spectronic Unicam Genesys 10UV spectropho-
tometer (Rochester, NY). The assay of AP activity was initiated by
the addition of 100 ml Sigma 104 solution (0.4 % [w/v] in 1M Tris-
HCl [pH 8.0]) to each sample. These were incubated at 37C until
a yellow color began to develop in the positive control sample (strain
JCB 570). The assay reaction was then stopped in one replicate of
samples by adding 100 ml of 1 M K2HPO4. Another measurement
Origamicin Inhibits HCV by Blocking PDI Function
1059of optical density at 420 nm was performed on these samples. The
remaining replicate was analyzed in a likewise manner at an arbitrary
later time point. Units of AP activity were calculated as follows:
AP activity = 10003 ðOD420t2OD420iÞ=ðt3OD600Þ;
where t = reaction time (in minutes, from the addition of Sigma 104 to
the addition of K2HPO4), OD420t = OD420 measurement after a reac-
tion t minutes in length, and OD420i = initial OD420 measurement
(i.e., prior to the addition of Sigma 104).
Supplemental Data
Supplemental Data include detailed protocols, chemical syntheses,
and functional data for the validation of the ABA analogs and can
be found at http://www.chembiol.com/cgi/content/full/13/10/1051/
DC1/.
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